ENOX2

Across TCGA pan-cancer cohorts, ENOX2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ENOX2 data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ENOX2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ENOX2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

GBM, LSCC, and LUAD are the cancer types where ENOX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.142	0.785	.017	6	view →
LSCC	DFS	Median	All	0.714	0.917	.009	6	view →
LUAD	DFS	Median	All	0.835	0.340	.010	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ENOX2–GBM (OS)

Open the GBM breakdown →